MD Research's  Instablog

MD Research
Send Message
I have a diverse background—as a financial journalist, resident physician, mixed martial artist, painter, entrepreneur, chemistry instructor and web developer—that enabled me to pioneer the “Integrated Investing Research” approach. I provide consulting to clients, both the retail and... More
My company:
Vincata Enterprises LLC
My blog:
Retail Investor 360
  • MannKind Corporation: The Truth About Lung Testing And Negative Sentiments On Afrezza 0 comments
    Aug 20, 2014 8:35 AM | about stocks: MNKD, SNY

    Published at Retail Investor 360: Friday, 15 August 2014 22:17Written by Doctor Hung V. Tran, MD, MS


    Disclosure: I am long on MNKD.

    360 Biotech Catalyst Keys

    • In contrast to the notion that the required lung testing or PFT is cumbersome and could hamper Afrezza sales, the test is quick and simple to perform with minimal discomfort to patients
    • Primary care settings such as clinics and physician offices already have at least one spirometer, which is commonly use to check lungs function for patients with asthma or COPD
    • Hospitals, clinics, and physicians' offices facing reduced insurance compensations will appreciate being able to offset their declining income by billing for the test.

    The Story. Despite significant improvements on the stock's fundamentals, many short contingents are still highly negative on the company. Prior to the FDA Advisory Committee (ADCOM) meeting on April 1, 2014, Adam Feuerstein a senior columnist of The Street prognosticated that MannKind will failed to received recommendation from the ADCOM. Needless to say, the ADCOM experts consist of physicians, scientists, industry leaders, and patients advocate voted 14-0 and 13-1 with high recommendation for Afrezza as treatment indications for both Type 1 and Type 2 diabetes, respectively. While it might seem an honorable act that Mr. Feuerstein apologized for his faulty prediction, it is rather hypocrisy because the senior columnist continues to attack MannKind. After the ADCOM, Mr. Feuerstein then stated with 60 percent confident that the FDA will not approved Afrezza. Contrary to his misguided journalism, the FDA approved Afrezza on June 27, 2014, for both Type 1 and Type 2 diabetes. It appeared that something never changes!

    If you'd like to read more, please follow this link.


    Disclosure: The author is long MNKD.

    Stocks: MNKD, SNY
Back To MD Research's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.